US Stock MarketDetailed Quotes

MREO Mereo BioPharma

Watchlist
  • 3.3550
  • +0.0450+1.36%
Trading Dec 19 09:35 ET
520.51MMarket Cap-11.18P/E (TTM)

About Mereo BioPharma Company

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Company Profile

SymbolMREO
Company NameMereo BioPharma
Listing DateApr 24, 2019
Issue Price17.62
Founded2015
CEODr. Denise Vera Scots-Knight, PhD
MarketNASDAQ
Employees33
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends12-31
Address1 Cavendish Place,4th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1G 0QF
Phone44-333-023-7300
Websitehttp://www.mereobiopharma.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Denise Vera Scots-Knight, PhD
  • Executive Director,Chief Executive Officer
  • 2.22M
  • Michael Stephen Wyzga
  • Non-Executive Director,Chairman
  • 156.80K
  • Justin Roberts
  • Non-Executive Director
  • --
  • Dr. Deepika Rachel Pakianathan
  • Non-Executive Director
  • 113.76K
  • Dr. Anders Olof Adolf Ekblom
  • Non-Executive Director
  • 121.31K
  • Pierre Jacquet
  • Non-Executive Director
  • 102.18K
  • Marc J. Yoskowitz
  • Non-Executive Director
  • 94.49K
  • Dr. Jeremy Bender
  • Non-Executive Director
  • 105.08K
  • Dr. Annalisa Mary Jenkins
  • Non-Executive Director
  • 100.96K
  • Daniel Shames
  • Non-Executive Director
  • 97.75K
  • Charles Sermon
  • General Counsel & Company Secretary
  • --
Heat List
US
Overall
Symbol
Price
% Chg

No Data